PF-592379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction but was never marketed. Unlike some other less selective D3 agonists, a research study showed that PF-592379 has little misuse potential in animal studies, and so was selected for further development and potentially human clinical trials. Development has since been discontinued.
See also List of investigational sexual dysfunction drugs 7-OH-DPAT PD-128,907 PF-219,061
References


